Arbutus Launches $230M Dutch Auction Tender, Shares Hit 52-Week High
ABUS sits 51% above its 52-week low of $3.44 on elevated volume (3.7× avg).
Summary
Arbutus Biopharma formalized its $230 million share repurchase with a modified Dutch auction tender offer, pricing the range at $5.00 to $5.75 per share. The offer is expected to begin Aug. 24 and expire Sept. 29, funded by cash on hand from the Moderna settlement. Shares jumped 9.4% to $5.22, a new 52-week high, as the market rewards the return of capital to shareholders. This follows the Q2 earnings report on Aug. 12 that first disclosed the buyback plan and the $178.4 million Moderna payment. The tender's premium to the pre-announcement price signals management's confidence in the company's valuation, while the ongoing patent litigation against Pfizer and BioNTech remains a key overhang.
At the time of this announcement, ABUS was trading at $5.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $3.44 to $5.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.